Hong Kong Biotech Breakthroughs

Sichuan Kelun-Biotech Biopharmaceutical

Market Cap: HK$109.5b

A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally.

CARsgen Therapeutics Holdings

Market Cap: HK$11.6b

An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China.

Beijing Luzhu Biotechnology

Market Cap: HK$4.6b

A biotechnology company, focuses on the research and development, production, and sale of human vaccines and therapeutic biologics to prevent and control infectious diseases, and treat cancer and autoimmune diseases in Mainland China.

Akeso

Market Cap: HK$125.1b

A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide.

Keymed Biosciences

Market Cap: HK$22.3b

A biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China and internationally.

Everest Medicines

Market Cap: HK$12.1b

A biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets.

GenFleet Therapeutics (Shanghai)

Market Cap: HK$16.0b

Operates as a biopharmaceutical company that focuses on developing novel treatment options in the fields of oncology that cover different lines of treatments of multiple solid tumors, as well as autoimmune and inflammatory diseases.

CanSino Biologics

Market Cap: HK$12.0b

Develops, manufactures, and commercializes vaccines in the People’s Republic of China.